Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022

Rhea-AI Summary

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) will report its first quarter 2022 financial results on May 4, 2022. A live conference call and webcast are scheduled for 8:00 AM ET on the same day, where the management will discuss financial outcomes and company updates. Investors can access the call via a provided phone number or through a webcast available on the company's website. Deciphera focuses on developing innovative cancer therapies, including QINLOCK, which is approved in multiple regions including the U.S. and Europe.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 4, 2022, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (877) 270-2148 (domestic) or (412) 902-6510 (international). A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005060/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals report its Q1 2022 financial results?

Deciphera Pharmaceuticals will report its Q1 2022 financial results on May 4, 2022.

What time is the Deciphera Pharmaceuticals conference call scheduled for?

The conference call is scheduled for 8:00 AM ET on May 4, 2022.

How can I access the Deciphera Pharmaceuticals earnings call?

You can access the earnings call by dialing (877) 270-2148 for domestic or (412) 902-6510 for international calls. A webcast will also be available on their website.

What is QINLOCK and where is it approved?

QINLOCK is Deciphera's switch-control inhibitor for fourth-line GIST, approved in the U.S., Europe, and several other regions.